Foundations Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Foundations Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	3,906 +5	+0.1%	+$274	﹤0.01%	1094
2026 Q1	$220K	Hold	3,901	–	–	﹤0.01%	1070
2025 Q4	$232K	Hold	3,901	–	–	﹤0.01%	1000
2025 Q3	$211K	Sell	3,901 -2	-0.1%	-$114	﹤0.01%	980
2025 Q2	$215K	Sell	3,903 -66	-2%	-$3.89K	﹤0.01%	866
2025 Q1	$281K	Sell	3,969 -97	-2%	-$6.53K	0.01%	728
2024 Q4	$267K	Buy	4,066 +161	+4%	+$10.8K	0.01%	689
2024 Q3	$274K	Buy	3,905 +4	+0.1%	+$334	0.01%	663
2024 Q2	$321K	Hold	3,901	–	–	0.01%	592
2024 Q1	$341K	Hold	3,901	–	–	0.01%	550
2023 Q4	$346K	Hold	3,901	–	–	0.01%	518
2023 Q3	$345K	Sell	3,901 -20	-0.5%	-$1.78K	0.01%	480
2023 Q2	$340K	Hold	3,921	–	–	0.01%	446
2023 Q1	$381K	Sell	3,921 -50	-1%	-$5.18K	0.01%	362
2022 Q4	$411K	Sell	3,971 -898	-18%	-$84.3K	0.02%	305
2022 Q3	$413K	Buy	+4,869	New	+$434K	0.02%	281

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Foundations Investment Advisors's BMRN Position: Q2 2026 in Review

Foundations Investment Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 0.13% in Q2 2026, buying an estimated $274 and bringing the position to 3,906 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Foundations Investment Advisors first reported a position in BMRN in Q3 2022 and has held it in 16 quarters since. The position peaked at $413K in Q3 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Foundations Investment Advisors held 3,906 shares of BioMarin Pharmaceuticals worth $224K as of Q2 2026.
Foundations Investment Advisors bought 5 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $274.
BioMarin Pharmaceuticals made up ﹤0.01% of Foundations Investment Advisors's portfolio in Q2 2026, its #1094 holding.
Foundations Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Foundations Investment Advisors's BioMarin Pharmaceuticals position peaked at $413K in Q3 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Foundations Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.